Company: Verseau Therapeutics
Job title: Co-founder & Chief Scientific Officer
Tatiana Novobrantseva is a Co-Founder and CSO of Verseau. Before Verseau, she consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer. Previously, Tatiana served as Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Tatiana’s accomplishments span multiple therapeutic areas in programs from discovery to development.
Completing the Immunity Cycle by Developing Macrophage Immunotherapies 2:30 pm
• Assess how macrophages and dendritic cells are biologically optimized to either induce or suppress an immune response • Understand why repolarizing pro-tumorigenic macrophages has been repeatedly identified as a crucial next step for the field of immuno-oncology • Outline how myeloid cell suppression has been fuelling the vicious cycle of the autoimmune disease •…Read more
day: Day One